Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1130-1136

  Lane, Andrew A ^a,b,c   Armand, Philippe ^a,b   Feng, Yang ^b   Neuberg, Donna S ^b   Abramson, Jeremy S ^b,c   Brown, Jennifer R ^a,b   Fisher, David C ^a,b   Lacasce, Ann S ^a,b   Jacobsen, Eric D ^a,b   McAfee, Steven L ^b,c   Spitzer, Thomas R ^b,c   Freedman, Arnold S ^a,b   Chen, Yi Bin ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Clinical results; Lymphoma and Hodgkin disease; Transplant toxicity

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; DOSE RESPONSE; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA; MALE; MEDIASTINUM; MIDDLE AGED; PNEUMONIA; RADIATION, IONIZING; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84861392281     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.645208     Document Type: Article

References (27)

1. Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin ' s lymphoma. Hematol Oncol Clin North Am 2007;21:943-960. (Pubitemid 47484144)
2. Wrench D, Gribben JG. Stem cell transplantation for non-Hodgkin ' s lymphoma. Hematol Oncol Clin North Am 2008;22:1051-1079, xi.
3. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2010. Available from: http://www.cibmtr.org
4. Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000;25:309-313. (Pubitemid 30103021)
5. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin ' s disease and non-Hodgkin ' s lymphoma: a dose-finding study. J Clin Oncol 1990;8:648-656. (Pubitemid 20127248)
6. Rubio C, Hill ME, Milan S, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin ' s disease. Br J Cancer 1997;75:1044-1048. (Pubitemid 27122624)
7. Weaver CH, Appelbaum FR, Petersen FB, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993;11:1329-1335. (Pubitemid 23199138)
8. Wong R, Rondon G, Saliba RM, et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 2003;31:1157-1163. (Pubitemid 36857374)
9. Benekli M, Smiley SL, Younis T, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin ' s lymphoma. Bone Marrow Transplant 2008;41:613-619. (Pubitemid 351523999)
10. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin ' s disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813. (Pubitemid 27121273)
11. Nademanee A, O' Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin ' s disease: results in 85 patients with analysis of prognostic factors. Blood 1995;85:1381-1390.
12. Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplantrelated mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47:1488-1494. (Pubitemid 44364012)
13. Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin ' s disease. J Clin Oncol 1991;9:1871-1879.
14. Todd NW, Peters WP, Ost AH, et al. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:1264-1270. (Pubitemid 23149889)
15. Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6: 387-394.
16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
17. Ager S, Mahendra P, Richards EM, et al. High-dose carmustine, etoposide and melphalan ( " BEM " ) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant 1996;17:335-340. (Pubitemid 26114488)
18. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26: 3777-3784.
19. Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med 1979;90:191-194. (Pubitemid 9117744)
20. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993;85:640-647. (Pubitemid 23120509)
21. Krivoy N, Hoffer E, Lurie Y, et al. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008;3:60-66. (Pubitemid 351227235)
22. Kalaycioglu M, Kavuru M, Tuason L, et al. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995;107:482-487.
23. Abushamaa AM, Sporn TA, Folz RJ. Oxidative stress and infl ammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Mol Physiol 2002;283:L336-L345. (Pubitemid 34803990)
24. Stahl W, Eisenbrand G. Comparative study on the influence of two 2-chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione-related enzymes in different organs of the rat. Free Radic Res Commun 1991;14:271-278.
25. Perez-Soler R, Saltz L. Cutaneous adverse Effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23: 5235-5246. (Pubitemid 46224035)
26. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-1183.
27. Schulz C, Boeck S, Heinemann V, et al. UGT1A1 genotyping: a predictor of irinotecan-associated side Effects and drug efficacy? Anticancer Drugs 2009;20:867-879.